By Fineline Cube 
Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming entered into an exclusive global licensing agreement with Ipsen for SIM0613, a next‑generation LRRC15‑targeted antibody‑drug conjugate (ADC). The deal, valued at up to $1.06 billion , marks Simcere Zaiming’s third out‑licensing in 2025, pushing Simcere’s cumulative transaction value to nearly $3.4 billion .
Transaction Overview
| Component | Details |
|---|---|
| Licensor | Simcere Zaiming (Simcere Pharmaceutical Group subsidiary) |
| Licensee | Ipsen (French biopharmaceutical company) |
| Asset | SIM0613 (LRRC15‑targeted ADC) |
| Territory | Global (excluding Greater China) |
| Deal Value | Up to $1.06 billion : upfront + development/regulatory/commercial milestones + tiered royalties |
| Cumulative Value | Simcere’s 2025 out‑licensing totals nearly $3.4 billion across 4 innovative drugs |
Drug Profile
| Attribute | SIM0613 | Competitive Advantage |
|---|---|---|
| Target | LRRC15 (highly expressed on solid tumors and CAFs) | Minimal expression in normal cells |
| Mechanism | ADC binds LRRC15 → endocytosis → cytotoxic payload release | Selective tumor cell killing |
| Features | Engineered for deep tumor and CAF penetration | Addresses stromal barriers in solid tumors |
| Preclinical Data | Significant anti‑tumor activity across multiple in vivo models | Best‑in‑class potential |
| Innovation | First LRRC15‑targeted ADC to enter global licensing | Novel target in ADC space |
Strategic Implications
- For Simcere: $3.4 billion cumulative value validates internal R&D engine; third 2025 out‑licensing demonstrates platform productivity; retains Greater China rights while monetizing global potential.
- For Ipsen: SIM0613 strengthens oncology pipeline with a differentiated ADC; LRRC15 target offers broad solid tumor applicability; global rights enable rapid development and commercialization.
- For Market: LRRC15 emerges as a promising ADC target; Simcere’s ADC platform positions as a global competitor; deal reflects premium valuations for early‑stage oncology assets.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding milestone achievements, clinical development timelines, and market impact. Actual results may differ due to scientific risks, competitive dynamics, or regulatory challenges.-Fineline Info & Tech